CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 71 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $50,000 | -65.0% | 17,000 | -45.2% | 0.00% | -60.0% |
| Q2 2020 | $143,000 | +20.2% | 31,000 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $119,000 | +9.2% | 31,000 | +6.9% | 0.01% | +25.0% |
| Q4 2019 | $109,000 | -29.2% | 29,000 | 0.0% | 0.00% | -20.0% |
| Q3 2019 | $154,000 | +38.7% | 29,000 | 0.0% | 0.01% | +25.0% |
| Q2 2019 | $111,000 | -19.6% | 29,000 | +7.4% | 0.00% | -20.0% |
| Q1 2019 | $138,000 | +165.4% | 27,000 | 0.0% | 0.01% | +150.0% |
| Q4 2018 | $52,000 | -46.9% | 27,000 | +3.8% | 0.00% | -33.3% |
| Q3 2018 | $98,000 | +21.0% | 26,000 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $81,000 | +30.6% | 26,000 | 0.0% | 0.00% | +50.0% |
| Q1 2018 | $62,000 | -39.2% | 26,000 | 0.0% | 0.00% | -50.0% |
| Q4 2017 | $102,000 | +54.5% | 26,000 | 0.0% | 0.00% | +33.3% |
| Q3 2017 | $66,000 | -8.3% | 26,000 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $72,000 | – | 26,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 5,517,885 | $22,789,000 | 2.29% |
| March Altus Capital Management LP | 80,890 | $334,000 | 1.94% |
| TANAKA CAPITAL MANAGEMENT INC | 111,693 | $462,000 | 1.15% |
| PURA VIDA INVESTMENTS, LLC | 395,000 | $1,951,000 | 1.00% |
| Broadfin Capital, LLC | 4,183,177 | $17,277,000 | 0.93% |
| Catalyst Capital Advisors LLC | 1,310,000 | $5,411,000 | 0.63% |
| SPHERA FUNDS MANAGEMENT LTD. | 1,200,000 | $4,956,000 | 0.48% |
| Baker Brothers Advisors | 7,335,692 | $30,296,000 | 0.27% |
| TURNER INVESTMENTS LLC | 286,370 | $1,183,000 | 0.22% |
| Perceptive Advisors | 851,200 | $3,515,000 | 0.21% |